Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden
David Tamborero, Maan Haj Rachid, Jorrit Boekel, Markus Jonsson & Ali Razzak
Medical Oncology, Oncology Data Science, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Rodrigo Dienstmann
Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Adria Lopez-Fernandez & Judith Balmaña
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Irene Braña, Elena Garralda, Josep Tabernero & Jordi Rodon
Department of Oncology and Pathology, Karolinska Institutet, Theme Cancer, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden
Luigi De Petris, Jeffrey Yachnin, Luigi De Petris & Jonas Bergh
Cancer Research UK Cambridge Centre, Cambridge, UK
Richard D. Baird, Richard Baird, Kenneth Seamon & Carlos Caldas
Département d’Innovation Thérapeutique et d’Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
Yohann Loriot, Christophe Massard & Patricia Martin-Romano
The Netherlands Cancer Institute, Amsterdam, the Netherlands
Frans Opdam & Emile Voest
NCT Trial Center, German Cancer Research Center, Heidelberg University Hospital, Heidelberg, Germany
Richard F. Schlenk
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Claudio Vernieri
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Claudio Vernieri
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Michele Masucci, Anders Wennborg & Ingemar Ernberg
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Xenia Villalobos & Elena Chavarria
Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Costanza Bono, Valentina Fornerone, Paola Gabaldi, Giovanni Scoazec & Giovanni Apolone
National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg, Germany
Stefan Fröhling
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
Claes Karlsson
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
Claes Karlsson
Oncode Institute, Utrecht, the Netherlands
Emile Voest
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Jordi Rodon
Clinical Proteomics Unit, Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Karolinska University Hospital, Stockholm, Sweden
Janne Lehtiö
Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, Cambridge, UK
Shubha Anand & Jose-Ezequiel Martin
Department of Scientific Administration, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Danny Baars & Ruud van der Noll
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Svetlana Bajalica-Lagercrantz
Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
Svetlana Bajalica-Lagercrantz
Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Mariska Bierkens & Gerrit Meijer
Department of Imaging and Physiology, Karolinska University Hospital, Stockholm, Sweden
Lennart Blomqvist
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Lennart Blomqvist
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
Gary J. Doherty
Institut Gustave Roussy, Villejuif, France
Arnauld Forest
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Felix Haglund
Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Felix Haglund
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Johan Hartman, Andreas Lundqvist & Christina von Gertten
Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Heidelberg, Germany
Peter Horak, Tanja Jutzi, Simon Kreutzfeldt, Petra Oberrauch & Laura Pelz
National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
Mary Kasanicki, Elena Provenzano & Marc Tischkowitz
NCT Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany
Lucian Le Cornet
Theme Cancer, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
Rolf Lewensohn
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Rolf Lewensohn
Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
Johan Lindberg
Business Development Area, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Carlos Lopez
Clinical Research Support Unit, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Susana Muñoz
DITEP– Drug Development Department, Institut Gustave Roussy, Villejuif, France
Maud Ngo Camus & Claudio Nicotra
Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Paolo Nuciforo
Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
Päivi Östling
Research Coordination Area, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Alejandro Piris-Gimenez
Tumor Genetic Lab, Institut Gustave Roussy, INSERM UMR 981, Villejuif, France
Etienne Rouleau
Cancer Core Europe, Institut Gustave Roussy, Villejuif, France
John Rowell
Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Omar Saavedra
Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Lizet van der Kolk
Drug development Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Maria Vieito
Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Daniel Vis & Lodewyk Wessels
Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Ana Vivancos
Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
Valtteri Wirta